Go Pro
→ The end may be near for these iconic stocks (From Chaikin Analytics) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Absci Corporation stock logo
ABSI
Absci
$9.65
$8.71
$2.24
▼
$12.06
$1.66B2.423.16 million shs7.73 million shs
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
$28.90
$30.30
$17.00
▼
$35.83
$1.43B1.35486,033 shs1.24 million shs
Century Therapeutics, Inc. stock logo
IPSC
Century Therapeutics
$1.86
$2.06
$0.44
▼
$3.04
$336.79M1.59459,361 shs1.37 million shs
TRAX
First Tracks Biotherapeutics
$38.60
$41.55
$14.72
▼
$49.91
$1.38BN/A651,453 shs2.59 million shs
Options Trading Made Easy - Download Now Cover
Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Absci Corporation stock logo
ABSI
Absci
0.00%+17.54%+1.05%+14.88%+269.73%
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
0.00%-0.34%-0.76%-11.62%+63.74%
Century Therapeutics, Inc. stock logo
IPSC
Century Therapeutics
0.00%-4.12%-10.14%-19.13%+289.77%
TRAX
First Tracks Biotherapeutics
0.00%+5.93%-10.46%+110.70%+3,859,999,900.00%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Absci Corporation stock logo
ABSI
Absci
$9.65
$8.71
$2.24
▼
$12.06
$1.66B2.423.16 million shs7.73 million shs
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
$28.90
$30.30
$17.00
▼
$35.83
$1.43B1.35486,033 shs1.24 million shs
Century Therapeutics, Inc. stock logo
IPSC
Century Therapeutics
$1.86
$2.06
$0.44
▼
$3.04
$336.79M1.59459,361 shs1.37 million shs
TRAX
First Tracks Biotherapeutics
$38.60
$41.55
$14.72
▼
$49.91
$1.38BN/A651,453 shs2.59 million shs
Options Trading Made Easy - Download Now Cover
Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Absci Corporation stock logo
ABSI
Absci
0.00%+17.54%+1.05%+14.88%+269.73%
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
0.00%-0.34%-0.76%-11.62%+63.74%
Century Therapeutics, Inc. stock logo
IPSC
Century Therapeutics
0.00%-4.12%-10.14%-19.13%+289.77%
TRAX
First Tracks Biotherapeutics
0.00%+5.93%-10.46%+110.70%+3,859,999,900.00%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Absci Corporation stock logo
ABSI
Absci
2.80
Moderate Buy$13.7142.12% Upside
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
2.70
Moderate Buy$44.8655.22% Upside
Century Therapeutics, Inc. stock logo
IPSC
Century Therapeutics
2.43
Hold$4.75155.38% Upside
TRAX
First Tracks Biotherapeutics
2.77
Moderate Buy$66.5572.40% Upside

Current Analyst Ratings Breakdown

Latest IPSC, AVBP, TRAX, and ABSI Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/18/2026
TRAX
First Tracks Biotherapeutics
Evercore Inc logo
Evercore
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOutperform$65.00
9/16/2026
TRAX
First Tracks Biotherapeutics
Guggenheim logo
Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$100.00
9/16/2026
TRAX
First Tracks Biotherapeutics
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy
9/16/2026
TRAX
First Tracks Biotherapeutics
Guggenheim logo
Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$100.00
9/16/2026
TRAX
First Tracks Biotherapeutics
Guggenheim logo
Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$100.00
9/9/2026
Absci Corporation stock logo
ABSI
Absci
Lifesci Capital logo
Lifesci Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOutperform
9/8/2026
Absci Corporation stock logo
ABSI
Absci
BTIG Research logo
BTIG Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price TargetBuy$15.00
9/8/2026
Absci Corporation stock logo
ABSI
Absci
BTIG Research logo
BTIG Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$13.00 ➝ $16.00
9/3/2026
TRAX
First Tracks Biotherapeutics
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$57.00
8/18/2026
TRAX
First Tracks Biotherapeutics
Wolfe Research logo
Wolfe Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOutperform$83.00
8/17/2026
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$44.00 ➝ $47.00
(Data available from 9/21/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Absci Corporation stock logo
ABSI
Absci
$2.80M591.44N/AN/A$1.26 per share7.66
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
N/AN/AN/AN/A$7.44 per shareN/A
Century Therapeutics, Inc. stock logo
IPSC
Century Therapeutics
$109.16M3.09$0.01 per share139.85$1.82 per share1.02
TRAX
First Tracks Biotherapeutics
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Absci Corporation stock logo
ABSI
Absci
-$115.18M-$0.80N/AN/AN/A-7,756.38%-61.71%-54.52%11/16/2026 (Estimated)
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
-$166.31M-$3.62N/AN/AN/AN/A-50.26%-46.66%11/16/2026 (Estimated)
Century Therapeutics, Inc. stock logo
IPSC
Century Therapeutics
-$9.58M-$0.93N/AN/AN/AN/A-49.51%-38.09%11/12/2026 (Estimated)
TRAX
First Tracks Biotherapeutics
N/A-$1.84N/AN/AN/AN/AN/AN/AN/A

Latest IPSC, AVBP, TRAX, and ABSI Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/12/2026Q2 2026
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
-$0.9873-$1.05-$0.0627-$1.05N/AN/A
8/12/2026Q2 2026
Century Therapeutics, Inc. stock logo
IPSC
Century Therapeutics
-$0.11-$0.17-$0.06-$0.17$2.17 millionN/A
8/12/2026Q2 2026
TRAX
First Tracks Biotherapeutics
-$0.74-$0.95-$0.21-$0.95N/AN/A
8/11/2026Q2 2026
Absci Corporation stock logo
ABSI
Absci
-$0.1910-$0.21-$0.0190-$0.21$0.92 million$0.32 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Absci Corporation stock logo
ABSI
Absci
N/AN/AN/AN/AN/A
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
N/AN/AN/AN/AN/A
Century Therapeutics, Inc. stock logo
IPSC
Century Therapeutics
N/AN/AN/AN/AN/A
TRAX
First Tracks Biotherapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Absci Corporation stock logo
ABSI
Absci
N/A
10.63
10.63
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
N/A
14.16
14.16
Century Therapeutics, Inc. stock logo
IPSC
Century Therapeutics
N/A
8.28
8.28
TRAX
First Tracks Biotherapeutics
N/A
14.28
14.28

Institutional Ownership

CompanyInstitutional Ownership
Absci Corporation stock logo
ABSI
Absci
52.05%
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
9.48%
Century Therapeutics, Inc. stock logo
IPSC
Century Therapeutics
50.20%
TRAX
First Tracks Biotherapeutics
N/A

Insider Ownership

CompanyInsider Ownership
Absci Corporation stock logo
ABSI
Absci
10.52%
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
8.58%
Century Therapeutics, Inc. stock logo
IPSC
Century Therapeutics
2.40%
TRAX
First Tracks Biotherapeutics
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Absci Corporation stock logo
ABSI
Absci
140171.61 million153.56 millionOptionable
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
7749.31 million45.08 millionN/A
Century Therapeutics, Inc. stock logo
IPSC
Century Therapeutics
78181.07 million176.73 millionOptionable
TRAX
First Tracks Biotherapeutics
10435.73 millionN/AN/A

Recent News About These Companies

First Tracks Biotherapeutics (NASDAQ:TRAX) Research Coverage Started at Guggenheim
September 19 at 2:38 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31032216
Evercore ISI Starts First Tracks Biotherapeutics (TRAX) at Outperform
September 18 at 7:17 AM  |  streetinsider.comhttps://www.streetinsider.com/New+Coverage/Evercore+ISI+Starts+First+Tracks+Biotherapeutics+%28TRAX%29+at+Outperform/27077856.html
Guggenheim initiates coverage of First Tracks Biotherapeutics with buy
September 17, 2026  |  msn.comhttps://www.msn.com/en-us/money/other/guggenheim-initiates-coverage-of-first-tracks-biotherapeutics-with-buy/ar-AA2cnIfO
First Tracks Biotherapeutics (NASDAQ:TRAX) Stock Rating Upgraded by Guggenheim
September 17, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-first-tracks-biotherapeutics-nasdaq-trax-stock-rating-upgraded-by-guggenheim-2026-09-17/
Guggenheim Starts First Tracks Biotherapeutics (TRAX) at Buy,
September 16, 2026  |  streetinsider.comhttps://www.streetinsider.com/Analyst+Comments/Guggenheim+Starts+First+Tracks+Biotherapeutics+%28TRAX%29+at+Buy%2C/27066556.html
Why First Tracks Biotherapeutics, Inc.’s (TRAX) Stock Is Up 5.01%
September 14, 2026  |  aaii.comA
Wellington Management Group LLP Makes New $1.16 Million Investment in First Tracks Biotherapeutics $TRAX
September 12, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-wellington-management-group-llp-makes-new-116-million-investment-in-first-tracks-biotherapeutics-trax-2026-09-12/
Opaleye Management Inc. Invests $1.31 Million in First Tracks Biotherapeutics $TRAX
September 11, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-opaleye-management-inc-invests-131-million-in-first-tracks-biotherapeutics-trax-2026-09-11/
J. Anthony Ware Sells 39,265 Shares of First Tracks Biotherapeutics (NASDAQ:TRAX) Stock
September 5, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-trax-insider-buying-and-selling-2026-09-05/
First Tracks Biotherapeutics (NASDAQ:TRAX) Downgraded to "Sell" Rating by Wall Street Zen
September 5, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-first-tracks-biotherapeutics-nasdaq-trax-downgraded-to-sell-rating-by-wall-street-zen-2026-09-05/
First Tracks Biotherapeutics (NASDAQ:TRAX) Director Sells $1,758,286.70 in Stock
September 4, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-first-tracks-biotherapeutics-nasdaq-trax-director-sells-175828670-in-stock-2026-09-04/
First Tracks Biotherapeutics' (TRAX) Buy Rating Reiterated at HC Wainwright
September 3, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-first-tracks-biotherapeutics-trax-buy-rating-reiterated-at-hc-wainwright-2026-09-03/
First Tracks Biotherapeutics (NASDAQ:TRAX) Receives Consensus Recommendation of "Moderate Buy" from Brokerages
August 31, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/consensus-first-tracks-biotherapeutics-nasdaq-trax-receives-consensus-recommendation-of-moderate-buy-from-brokerages-2026-08-31/
First Tracks Biotherapeutics Inc (TRAX)
August 30, 2026  |  de.investing.comhttps://de.investing.com/equities/first-tracks-biotherapeutics-financial-summary
First Tracks Biotherapeutics Announces Participation in September Investor Conferences
August 26, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/26/3351693/0/en/first-tracks-biotherapeutics-announces-participation-in-september-investor-conferences.html
Analysts Offer Insights on NA Companies: Cerebras Systems, Inc. Class A (CBRS), CitroTech (CITR) and First Tracks Biotherapeutics Inc (TRAX)
August 14, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/CBRS/pressreleases/3848972/analysts-offer-insights-on-na-companies-cerebras-systems-inc-class-a-cbrs-citrotech-citr-and-first-tracks-biotherapeutics-inc-trax/
Barclays Sticks to Its Buy Rating for First Tracks Biotherapeutics Inc (TRAX)
August 14, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/3846416/barclays-sticks-to-its-buy-rating-for-first-tracks-biotherapeutics-inc-trax/
First Tracks Biotherapeutics Analysts Increase Their Forecasts After Q2 Results
August 13, 2026  |  benzinga.comhttps://www.benzinga.com/analyst-stock-ratings/price-target/26/08/61173753/first-tracks-biotherapeutics-analysts-increase-their-forecasts-after-q2-results
First Tracks Biotherapeutics Announces Second Quarter 2026 Financial Results and Provides Business Update
August 12, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/12/3344098/0/en/first-tracks-biotherapeutics-announces-second-quarter-2026-financial-results-and-provides-business-update.html
First Tracks Biotherapeutics Inc (TRAX) Gets a Buy from Wells Fargo
July 29, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/3518217/first-tracks-biotherapeutics-inc-trax-gets-a-buy-from-wells-fargo/
TRAX stock hits all-time high — what's driving the super rally?
July 10, 2026  |  msn.comhttps://www.msn.com/en-in/autos/general/trax-stock-hits-all-time-high-what-s-driving-the-super-rally/ar-AA27EVaA

New MarketBeat Followers Over Time

Media Sentiment Over Time

Absci stock logo

Absci NASDAQ:ABSI

$9.65 0.00 (0.00%)
Closing price 09/18/2026 04:00 PM Eastern
Extended Trading
$9.82 +0.17 (+1.76%)
As of 06:52 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Absci Corporation operates as a data-first generative artificial intelligence (AI) drug creation company in the United States. The company combines AI with scalable wet lab technologies to create biologics for patients. Its integrated drug creation platform is designed to improve upon traditional biologic drug discovery by using AI to simultaneously optimize multiple drug characteristics that may be important to development and therapeutic benefit. The company was founded in 2011 and is headquartered in Vancouver, Washington.

ArriVent BioPharma stock logo

ArriVent BioPharma NASDAQ:AVBP

$28.90 0.00 (0.00%)
Closing price 09/18/2026 04:00 PM Eastern
Extended Trading
$28.90 0.00 (-0.01%)
As of 06:40 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors. In addition, the company develops Furmonertinib, a third-generation tyrosine kinase inhibitor that is in multiple clinical trials across a range of epidermal growth factor receptor mutations (EFGRm) in non-small cell lung cancer (NSCLC), including a phase 3 clinical trial for treatment of patients with metastatic EFGRm NSCLC; phase 1b clinical trial for treatment of patients with NSCLC with other EGFR mutations and NSCLC with HER2 Exon 20 insertion mutations; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. to discover and develop antibody drug conjugates (ADCs) with improved activity and safety over single target bivalent ADCs; and Shanghai Allist Pharmaceuticals Co., Ltd. to develop and commercialize Furmonertinib. The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.

Century Therapeutics stock logo

Century Therapeutics NASDAQ:IPSC

$1.86 0.00 (0.00%)
Closing price 09/18/2026 04:00 PM Eastern
Extended Trading
$1.86 0.00 (0.00%)
As of 04:02 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Century Therapeutics, Inc., a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma. The company is also involved in the development of CNTY-102, a bi-specific CD19 + CD22 CAR-iT product candidate for relapsed, refractory B-cell lymphoma and other B-cell malignancies; and CNTY-107, a Nectin-4 CAR-iT targeted product candidate for Nectin-4 positive solid tumors. In addition, it has a strategic collaboration with Bristol-Myers Squibb Company to develop and commercialize up to four iNK or iT programs, including CNTY-104, a multi-specific collaboration program targeting acute myeloid leukemia; and CNTY-106, a multi-specific collaboration program for multiple myeloma. The company was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.

First Tracks Biotherapeutics NASDAQ:TRAX

$38.60 0.00 (0.00%)
Closing price 09/18/2026 04:00 PM Eastern
Extended Trading
$38.87 +0.27 (+0.71%)
As of 05:37 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

First Tracks Biotherapeutics is a clinical stage biotechnology company advancing antibody therapies which modulate immune pathways implicated in autoimmune and inflammatory diseases. Its pipeline includes ANB033 and ANB101. First Tracks Biotherapeutics is based in SAN DIEGO.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas